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Abstract
Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the
leading cause of premature mortality in low and middle income countries (LMICs).
Identifying and managing individuals at high risk of CVD is an important strategy to
prevent and control CVD, in addition to multisectoral population-based interventions
to reduce CVD risk factors in the entire population.
Methods: We describe key public health considerations in identifying and managing
individuals at high risk of CVD in LMICs.
Results: A main objective of any strategy to identify individuals at high CVD risk is to
maximize the number of CVD events averted while minimizing the numbers of
individuals needing treatment. Scores estimating the total risk of CVD (e.g. ten-year risk
of fatal and non-fatal CVD) are available for LMICs, and are based on the main CVD risk
factors (history of CVD, age, sex, tobacco use, blood pressure, blood cholesterol and
diabetes status). Opportunistic screening of CVD risk factors enables identification of
persons with high CVD risk, but this strategy can be widely applied in low resource
settings only if cost effective interventions are used (e.g. the WHO Package of Essential
NCD interventions for primary health care in low resource settings package) and if
treatment (generally for years) can be sustained, including continued availability of
affordable medications and funding mechanisms that allow people to purchase
medications without impoverishing them (e.g. universal access to health care). This
also emphasises the need to re-orient health systems in LMICs towards chronic
diseases management.
Conclusion: The large burden of CVD in LMICs and the fact that persons with high
CVD can be identified and managed along cost-effective interventions mean that
health systems need to be structured in a way that encourages patient registration,
opportunistic screening of CVD risk factors, efficient procedures for the management
of chronic conditions (e.g. task sharing) and provision of affordable treatment for those
with high CVD risk. The focus needs to be in primary care because that is where most
of the population can access health care and because CVD programmes can be run
effectively at this level.
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Burden of cardiovascular disease and impact in LMICs
Cardiovascular disease (CVD), mainly heart attack and stroke, is the leading cause of
premature mortality and morbidity worldwide [1–3]. An estimated 38 million of the 56
million deaths that occurred globally in 2012 were due to noncommunicable diseases
(NCDs) (i.e. CVD, cancer, diabetes and chronic respiratory diseases), with CVD
accounting for 46 % of NCD deaths. In 2008, 80 % of all deaths from NCDs occurred
in low- and middle-income countries (LMICs). The good news is that premature fatal and
non-fatal CVD is largely preventable, and feasible cost-effective interventions exist [4, 5],
which emphasizes the need to respond to CVD and other leading NCDs in all countries. In
most LMICs, the majority of people at high risk of CVD, which largely correspond to those
people with hypertension, high blood cholesterol and/or diabetes, are not aware of having
these conditions and do not appreciate that these are risk factors for CVD or that these
conditions can be controlled with effective management [6, 7]. In addition, many people in
LMICs are unaware of the lifestyle behaviours that are associated with increased risk of
CVD and other NCDs, such as tobacco use, harmful use of alcohol, unhealthy diet and
physical inactivity.
Strategies to prevent CVD in populations
There are two main strategies to prevent CVD: population and high-risk [8]. Advan-
tages and disadvantages of these two strategies are summarized in Fig. 1. Population
strategies involve multisectoral interventions to reduce risk factors in the population.
They deploy small effects at the individual level (i.e., small reduction in risk factors)
and are “good for all” (e.g. tobacco taxation or reduction of salt, sugar and trans-fats in
processed foods). The financial cost of their implementation is often low and some
interventions can generate substantial revenue (e.g. taxes on tobacco and alcohol). On
the other hand, the health and social costs tend to be high when the determinants of
diseases are related to profitable production of goods (e.g., tobacco, alcohol or food
industries).
Fig. 1 Selected characteristics of the population strategy (left) and high risk strategy (right)
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High-risk strategies involve health care services; they bring large benefit (i.e. large
reduction of some risk factors) to those persons treated, are “good for some”, but
require the explicit engagement of individuals (e.g. long-term adherence to medication).
The financial cost is often high because management of NCDs often requires life-long
clinical medications (e.g. hypertension, dyslipidaemia, diabetes, etc.). These interven-
tions tend to benefit from a broad support by patients, health professionals and govern-
ment because their effect is clinically apparent and immediate. Nevertheless there are a
number of high risk interventions that are cost-effective and feasible.
Screening of individuals at high CVD risk can also be viewed as a strategy to detect
sub-clinical CVD (e.g. coronary atherosclerosis, increased artery intima-media thick-
ness, enlarged left myocardial ventricular mass, endothelial artery dysfunction, etc.) and
treatment for these persons viewed as a mean to improve the prognosis of such
subclinical CVD condition(s). In this paper, we consider CVD as clinical stroke or myo-
cardial infarction, and the identification and treatment of individuals at high CVD risk
among those who have not yet developed overt CVD) as a means to prevent or delay
the occurrence of overt CVD.
Persons who have already developed CVD need to be treated to both improve their
immediate prognosis and reduce the occurrence of further acute CVD events. Clinical
treatment of acute CVD can be very effective, e.g. coronary revascularization (coronary
artery bypass surgery) or percutaneous coronary intervention), but these interventions
tend to be complex and costly. Because persons who have already developed clinical
CVD have a very high risk of developing further events, it is a priority to identify them
in order to provide long-term clinical management to reduce their CVD risk.
The optimal balance between population and high-risk strategies differs according to
epidemiological and resource situations in different populations. However, any program
devoted to CVD prevention and control has to include a mix of both high-risk inter-
ventions (aimed at providing cost effective treatment to selected persons at high risk of
CVD, or with CVD) and population wide interventions (aimed at reducing the levels of
upstream CVD determinants in the entire population). Population and high-risk strat-
egies mutually reinforce each other, e.g. those treated for CVD conditions may be
inclined to support public health interventions, while implementation of public health
interventions help sensitize the individuals about the need to adopt healthy behaviours
and take long-term treatment when indicated.
In high-income Western countries, the age-standardized CVD mortality rate has
decreased by more than 70 % in the past four decades. Approximately 50–60 % of this
reduction has been attributed to population-based interventions (i.e. reduction of CVD
risk factors in the population through public health measures targeting the entire popu-
lation) and 40–50 % to clinical management at the individual level [9, 10]. The substan-
tial contribution of the high-risk strategy to reduce CVD morbidity and mortality has
also been observed in LMICs, for example in Brazil [11, 12].
Priority interventions
There is now consensus across the globe on the need to address priority NCDs in
LMICs. The World Health Assembly (WHA) has agreed on 9 voluntary global targets
for the prevention and control of NCDs, including a 25 % relative reduction by 2025 in
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premature mortality (age 30–70) from CVD, cancer, diabetes, or chronic respiratory
diseases from the 2010 baseline (Table 1).
Cost effective, affordable and scalable interventions, both at population-wide level and
in high-risk groups, are described in the World Health Organization (WHO) Global NCD
Action Plan, 2013–2020 (Table 2) [5, 13] and in the 2014 NCD Status Report [14]. These
interventions were determined through both technical (expert reviews) and political
(WHO Member States) consultations. Prioritizing cost-effective interventions is import-
ant to maximize public health gain within often very limited resources [15].
High-risk interventions are relevant for four of the 9 voluntary global targets: 1) 25 %
relative reduction in the prevalence of blood pressure levels; 2) halting the rise of
diabetes and obesity; 3) at least 50 % of eligible people receiving drug therapy to pre-
vent heart attacks and strokes; and 4) 80 % availability of the affordable basic technolo-
gies and essential medicines to treat major NCDs. A set of 25 indicators to monitor
progress toward the 9 targets has also been agreed by the WHA.
It has been estimated that implementing a package of very-cost effective, or “best
buy”, population and high-risk strategic interventions for the prevention and control of
the four principal NCDs would cost US$ 0.88, US$ 1.45 and US$ 2.91 per capita per
year for low-income countries, lower middle-income countries and upper middle-
income countries, respectively, which respectively spend US$ 22, US$ 74, and US$ 412
for total health expenditure per capita annually [16]. High-risk strategies would account
for the largest share of the cost of the full package (Fig. 2) and treatment for persons at
high CVD risk would account for the largest share of resources for high risk strategies
for the main NCDs (Fig. 3) [16]. This underlies the need to carefully design high-risk
strategies targeting persons at high CVD risk, particularly in LMICs.
Assessing CVD risk
The majority of CVD guidelines are from high-income countries and focus on single
risk factors with regards to prevention of CVD, rather than using an absolute risk
approach. For example a number of guidelines suggest initiating anti-hypertensive
Table 1 Main targets for intervention to prevent main NCDs, including CVD, to be achieved by
2025 as compared to baseline in 2010
Mortality and
morbidity
1 25% reduction in mortality from CVD, cancer, diabetes, or chronic respiratory diseases
Behavioural risk
factors
2 10% reduction in harmful use of alcohol
3 10% reduction in the prevalence of insufficient physical activity
4 30% reduction in salt intake
5 30% reduction in the prevalence of smoking in adults
Biological risk factors 6 25% relative reduction in the prevalence of raised BP
7 0% increase in the prevalence of diabetes and obesity
National systems
response
8 At least 50% of eligible people receive drug therapy and counselling (including
glycemic control) to prevent heart attacks and strokes
9 At least 80% availability of affordable basic technologies and essential medicines for
NCDs in both public and private facilities
NCD noncommunicable diseases, CVD cardiovascular disease
Adapted from WHO [5]
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Table 2 Cost effective interventions for the prevention and control of NCDs as reported in the
WHO Global Action Plan 2013–2020
Clinical Risk factor/
disease (DALYs
in millions; %
global burden)
Interventions (bold are
‘best buys’, others are
‘good buys’)
Averted
burden
CE Implementation
cost
Feasibility
(health
system
constraints)
Tobacco use
(>50m
DALYs;3.7%
global burden)
Raise tax on tobacco Combined
effect:
CE Very low cost Highly
feasible;
strong
framework
(FCTC)
Ban tobacco advertising 25–30 million
DALYs (>50%
tobacco
burden)
Ban smoking in public/
work places
Health warning on
danger of smoking
C Offer counselling to
smokers
Quite
CE
Quite low cost Feasible
(PHC)
Harmful use of
alcohol (>50m
DALYs; 4.5% GB)
Restrict access to retailed
alcohol
Combined
effect:
Very CE Very low cost Highly
feasible
Enforce bans on alcohol
advertising
5–10 m
DALYs (10–
20% alcohol
burden)Raise taxes on alcohol
Enforce drink-driving
laws
Quite
CE
Quite low cost Intersectoral
Feasible
(PHC)
Offer brief advice for
hazardous drinking
Unhealthy diet
(15–30m DALYs;
1–2% GB)
Reduce salt intake Salt
reduction:
Very CE Very low cost Highly
feasible
Replace transfat with
polyunsaturated fat
5 m DALYs
Promote public
awareness about diet
Restrict marketing of
food and beverages to
children
NA Very CE Very low cost Highly
feasible
Replace saturated fat
with unsaturated fat
Manage food taxes and
subsidies
Provide health education
in worksites
Less CE Quite low cost Highly
feasible
Promote healthy eating
in schools
C Offer counselling in
primary care
Quite
CE
Higher cost Feasible
(PHC)
Physical
inactivity
Promote physical activity
(mass media)
NA Very CE Very low cost Highly
feasible
(>30m
DALYs;2.1% GB)
Promote physical activity
(communities) Support
active transport
strategies
Not
assessed
Not assessed
globally
Intersectoral
action
Promote physical activity
in worksites
Quite
CE
Higher cost Feasible
(PHC)
Promote physical activity
in schools
Less CE Higher cost Feasible
C Offer counselling in
primary care
C Very CE Quite low cost
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medication for all persons with blood pressure ≥140/90 mmHg, even where the risk of
CVD is low [17, 18]. However, when interventions involve potential long term treat-
ment at the individual level, and implicitly significant resources, it is important to
develop strategies that can maximize the numbers of CVD events averted and minimize
the numbers of persons who need to be treated. This is important for all countries, but
particularly for LMICs with their limited resources. CVD risk scores have been devel-
oped and are based on a limited number of main CVD risk factors (e.g. age, sex, hyper-
tension, smoking, cholesterol, diabetes). A main principle underlying all CVD risk
scores is that lowering blood pressure, or lowering blood cholesterol, provides similar
relative risk reduction at all levels of baseline CVD risk, but progressively greater abso-
lute risk reduction as the baseline CVD risk increases [19–23]. As a result, it is most ef-
ficient to provide treatment to those persons with the highest total CVD risk [24].
Providing treatment to individuals with a risk for developing fatal or non-fatal CVD lar-
ger than 20-30% in the next 10 years is typically considered a very cost-effective or a
“best buy” intervention to reduce CVD in LMICs. A “best buy” intervention generates
an extra year of healthy life for a cost that falls below the average annual gross domes-
tic product [GDP] income per person. Risk scores are also calibrated to account for the
background CVD risk in a particular population, which underlies that different risk
scores have been developed in different regions.
Nevertheless, because the levels of risk factors tend to track over time in a same
individual (e.g. youths with high blood pressure are likely to become adults with
high blood pressure or inversely, adults with high blood pressure are likely to have
had high blood pressure during their youth), some experts maintain that interven-
ing at an earlier stage when the overall risk is only intermediate (which often
means at an earlier age and/or at a lower total CVD risk) would help prevent the
transition from a “moderate” to a “high” risk of CVD and reduce the number of
treatment failures that can occur when treatment is initiated at the high risk stage
[25–27]. Furthermore, there is some evidence to treat high risk individuals to more
stringent targets (e.g. BP levels <120/80 mmHg) [28], and to extend treatment in
primary prevention to individuals at lower CVD risk [29] to achieve larger CVD
prevention and sustain CVD reduction over time, although the recent trends to ex-
tend treatment to increasingly low risk persons raise a number of issues [30].
A further concern is that despite the fact that CVD risk scores have good accur-
acy in predicting CVD risk [31], prediction of future CVD events is less reliable at
Table 2 Cost effective interventions for the prevention and control of NCDs as reported in the
WHO Global Action Plan 2013–2020 (Continued)
CVD and
diabetes (170 m
D; 11% GB)
Counselling & multidrug
therapy for CVD and
diabetes if 10-year risk of
CVD ≥30%
60 m DALYs
(35% CVD
burden)
Feasible
(PHC)
C Aspirin for acute
myocardial infarction
4 m
(2% CVD B)
Feasible
(PHC)
C Multidrug therapy if 10-
year risk of CVD ≥20%
70 m
(40% CVD B)
Quite
CE
Higher cost Feasible
(PHC)
Abbreviations: C clinical intervention (i.e. all others are public health interventions), B burden, CA cancer, CE cost effective,
CVD cardiovascular diseases, DALY or D disability adjusted years of life lost, FCTC framework convention on tobacco
control, GB global burden, m million, NA not available, PHC primary health care
Interventions in bold/blue are very cost effective (“best buys”), i.e. generate an extra year of healthy life for a cost that
falls below the average annual income or gross domestic product per person
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the individual level [32]. Large numbers of CVD events in the population arise
from the large numbers of persons with only low or moderate CVD risk. For
example, more than 50 % of all CVD events in the UK arise from persons with
CVD risk lower than 10 % using the QRISK2 score [33]. Furthermore, CVD risk
scores have not been developed from actual data in most LMICs because of a lack
of population-based cohort studies, and several issues must be considered when
calibrating risk scores from one population to others [34], e.g. from high income
countries to LMICs.
Fig. 2 Estimated cost of scaling up best buy interventions to prevent NCDs in LMICs. Reproduced with
permission from WHO [16]
Fig. 3 Estimated cost of scaling up high risk interventions to prevent CVD and other NCDs in LMICs.
Reproduced with permission from WHO [16]
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CVD risk charts in LMICs
WHO has issued CVD prediction charts to assess the 10-year risk of fatal or non-fatal
CVD that can be applied in different regions of the world [35–38]. The CVD score
requires information on a person’s age, sex, smoking status, diabetes status, blood pres-
sure and blood cholesterol. Risk charts also exist when levels of cholesterol cannot be
measured [39]. In the WHO PEN package, a mixed approach to high CVD risk is
proposed [40]. CVD medications are indicated for persons with very high CVD risk
(i.e. 10-year CVD risk ≥30 %), or for persons with blood pressure ≥160/100 mmHg
alone, or with cholesterol ≥8.0 mmol/l alone (who may not necessarily have a high total
CVD risk).
Table 3 shows the estimated numbers of persons who would need to be treated to
prevent CVD and the related costs, according to different high-risk scenarios. These
estimates are based on the distribution of CVD risk factors assessed in a population-
based survey of CVD risk factors in the Republic of Seychelles and are limited to the
sole costs of medications related to treatment of high CVD risk [41]. Cost estimates are
based on generic drugs procured mainly from India (i.e. around 10 times less expensive
than in western countries) and do not account for acute care of incident or prevalent
CVD, medical visits and biological or other examinations.
Who should be assessed for CVD risk?
Screening for CVD risk implies assessing individual CVD risk factors included in the
CVD risk score (Table 4) [42–46]. However, because assessing CVD risk can involve
lifelong treatment, screening strategies in all countries, and particularly in LMICs, must
take into account available resources and competing needs. Screening of CVD risk may
best achieved using opportunistic screening of selected CVD risk factors at the primary
health care level, considering that a majority of the population will seek health care at
some point of time. Guidelines should be adapted to local circumstances and specify
Table 3 Estimated impact and cost of different high risk strategies to prevent CVD in the
Seychelles based on data in 2004
Treatment
strategy
No.
eligible
to treat
Number of
CVD events
averted
Number needed to
treat to avoid 1 CVD
event
Total cost of
medications (in
US$ millions)
Cost of medications
(US$) to avert 1 CVD
event
BP ≥140/90
mmHg
44′899 127 354 1.84 14′534
Total
cholesterol
≥6.2 mmol/l
28′317 39 727 1.24 31′831
High BP or
high
cholesterol
59′741 157 379 3.89 24′678
Risk ≥10% 10′837 137 79 1.03 7′499
Risk ≥20% 5′114 92 56 0.49 5′291
Risk ≥20%, BP
≥160/100, TC
≥8.0
20′653 147 140 1.96 13′307
Current
situation
37′667 103 366 2.45 23′789
Adapted from Bovet et al [41]
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who should be screened, for what, at which age, and at which time intervals. In many
countries, there are pressures from the private sector, including private health care
systems, which encourage screening of a variety of non essential CVD markers [47].
WHO has published a set of tools for the assessment and management of CVD risk for
the prevention of heart attack and stroke in primary care, including hypertension and
diabetes. The protocol considers several conditions, including age; tobacco use; in-
creased waist circumference; known hypertension; known diabetes; history of prema-
ture CVD in first degree relatives; and history of diabetes or kidney disease in first
degree relatives [40]. Of note, identifying individuals with diabetes is useful both to
assess CVD risk (diabetes is a risk factor that doubles an individual’s total CVD risk)
and for targeted early detection and treatment of diabetes per se, as diabetes also is a
disease incurring complications not related to CVD. WHO is currently developing
guidelines on screening for CVD risk and diabetes.
Management of persons with CVD risk at primary health care level in LMICs
Guidelines on screening for CVD risk need to be developed alongside guidelines on
how those persons identified at risk should be managed. Guidelines should include
evidence-based interventions which are affordable and feasible for a particular environ-
ment. The PEN package tools provide specific guidance for the management among pa-
tients with the main NCDs that can be used in low resources settings for both persons
with CVD (heart attack and stroke) and those at high risk of CVD [40]. Management
for both primary and secondary prevention of CVD needs to have a strong focus on
risk factor reduction through both a healthier lifestyle and medications to control blood
pressure, blood lipids, and diabetes. Further description of the management of CVD
and its risk factors is beyond the scope of this review, particularly taking into account
that clinical management of acute CVD events and those at high risk CVD risk will
largely depend on resources available; further information is available elsewhere [42,
48]. Of note, a number of effective interventions to reduce CVD risk do not require
drug therapy [42], e.g. advising smokers to quit [49] or encouraging people to adopt a
healthy diet (e.g. calorie intake and salt reduction) and regular physical activity [50].
Challenges related to assessment and management of high CVD risk
Overdiagnosis
A major caveat when assessing a CVD risk in the population is avoiding overdiagnosis
[51]. Overdiagnosis can result in inappropriate treatment that can be both hazardous to
Table 4 Recommendations of the U.S. Preventive Service Task Force (USPSTF) for the screening of
hypertension, dyslipidemia and diabetes in adults
Condition Recommendations
High blood
pressure
Recommendation to screen for high blood pressure in adults 18 and over.
Abnormal blood
lipids
Recommendation to screen men aged 35 and older for lipid disorders;
Recommendation to screen women aged 45 and older for lipid disorders if they are at
increased risk for coronary heart disease.
Diabetes Recommendation to screen for abnormal blood glucose and type 2 diabetes mellitus in
adults who are at increased risk for diabetes.
Adapted from different recommendations from USPSTF [43–46]
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the patients and a waste of scarce resources. In one study in Tanzania, only half of all
those who had high blood pressure on a first reading (≥160/95 mmHg, i.e. at a level
requiring treatment irrespective of total CVD risk) still had high blood pressure (≥140/
90 mmHg) at a fourth medical visit several weeks later, with no treatment given in the
interval [52]. These findings are explained by two distinct phenomena. The first mech-
anism is the well-known “regression to the mean”, i.e. the fact that a number of
measurements that are at extreme values (high or low) on a first measurement will tend
to move toward values closer to the mean value over subsequent measurements. This
problem underlies the need to measure risk factors (particularly BP and blood glucose)
on several different days before a definite diagnosis is done.
The second mechanism is the “white coat effect” whereby blood pressure measured by a
doctor is artificially high because of anxiety related to the procedure. Indeed, blood pressure
readings tend to be lower if they are self-measured or measured by other health care staff. If
patients are started on treatment with an erroneous diagnosis of hypertension, a subsequent
decrease in blood pressure can be erroneously attributed to antihypertensive care and treat-
ment may be continued indefinitely. In all countries, including resource limited settings,
home blood pressure monitoring (e.g. self measurement at home of blood pressure for a
few days using an electronic monitoring device) can be a useful strategy to reduce false posi-
tive hypertension cases when considering the high cost of overdiagnosis, which may result
in unnecessary treatment for many years and potential harmful side effects.
Adherence to treatment
Low adherence to treatment is another important challenge. Adherence as low as 50 %
was found for treatment of hypertension and other CVD risk factors in both high and
low income countries [53–55]. In Dar es Salaam (Tanzania), only 30 % of those diag-
nosed with hypertension were accessing health care at 12 months and less that 3 %
were on treatment [56]. Explanations for this pattern include out-of-pocket expenditure
for health care, which makes long term treatment too expensive; the fact that health
care is not a priority for people with asymptomatic conditions; and a variety of emo-
tional and other barriers related to perception by patients of NCDs and chronic treat-
ment [57]. Ensuring that a patient has sufficient understanding of his/her CVD
condition, the underlying causes, and the reasons for treatment, is important in encour-
aging adherence to long-term treatment. However health care professionals rarely have
sufficient time, understand the importance of, or are rarely sufficiently incentivized to
explain to their patients the need to comply with treatment. A number of other factors
aimed at strengthening the entire health system have been identified to improve adher-
ence to treatment for chronic conditions [58, 59].
Fixed-dose multidrug therapy
Some authors have recommended a radically simplified treatment strategy by using
two simple markers (age and sex) as the basis for determining treatment and one sin-
gle multipurpose fixed dose drug combination to lower blood pressure, blood choles-
terol and aspirin ( i.e., the “polypill”) [60]. According to this strategy, a fixed-dose
combination medication taken by all males aged ≥55 years, irrespective of their levels
of other CVD risk factors, could reduce CVD by more than 80 %. Proponents of this
approach highlight that this strategy has the potential to minimize the need for diag-
nostic testing, reduce requirements for medical follow-up, simplify treatment guidelines,
enable greater task sharing for health care delivery, and enable procurement of
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drugs at lower costs [61]. There is no definite evidence to support broad use of fixed-
dose combination therapy as yet, and efficacy, long-term risks, sustainability, and cost
effectiveness of this strategy remain to be established before considering widespread
use of fixed-dose combinations but evaluations are ongoing [62]. In any case, any use
of a polypill should not undermine comprehensive public health approaches to NCD
prevention and control and efforts to strengthen health systems in LMICs.
Strengthening health systems for management of NCDs
The identification of CVD risk factors, and subsequent management when needed,
require a strong and sustainable health system covering the whole population.
Health systems in many LMICs need rapid orientation towards care of chronic
conditions, including CVD and other NCDs, an area that has hitherto been
neglected. This requires strengthening the health system across all its dimensions.
A primary task is the appropriate education of the health workforce, both in clin-
ical care and in public health, in order to improve the understanding of chronic
diseases, including screening and long-term follow up. Other areas needing
strengthening include service delivery, health information systems, access to essen-
tial medicines, sustainable financing, and leadership and accountable governance
[63].
The focus for NCD prevention and control in all countries needs to be in pri-
mary care, as this is where interventions are most cost-effective and feasible, and
can reach the largest number of people. Countries therefore need to ensure that
their health sector strategies articulate costed plans for scaling up the health sys-
tem response to NCDs, with particular emphasis on primary health care. An effect-
ive primary care response requires the training of health professionals in the
diagnosis and management of CVD and its risk factors; the production and avail-
ability of concise and locally relevant guidelines on priority cost-effective interven-
tions for CVD risk reduction [64]; the development of registries and information
systems allowing easy follow up of patients’ CVD risk parameters over time (as
well as records of informed preferences of “engaged patients” about their treat-
ment); availability of simple and reliable equipment for assessing CVD risk (mainly
hypertension, diabetes and dyslipidaemia); sustained availability of affordable essen-
tial priority medications for CVD risk reduction (which may include as few as a
dozen of drugs for reducing CVD risk); and task shifting/task sharing so that man-
agement and/or follow-up of patients at high CVD risk (e.g. patient with well con-
trolled hypertension and/or diabetes) can be performed by health professionals
other than doctors [65–67]. A recent trial showed that a simplified cardiovascular
management program conducted by community health workers at primary health
care level improved quality of care and clinical outcomes in resource-poor settings
in China and India compared to usual care [68].
More generally, management of NCDs in LMICs is a multi-billion dollar market
for pharmaceutical and allied industries. It is therefore important that good govern-
ance, continued monitoring, involvement of the civil society, and adequate regula-
tory frames are set up so that treatment and prevention of CVD and other NCDs
are not solely left to commercial interests [69–72].
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Access to health care
Treatment costs are often paid out-of-pocket in LMICs and the cost of monthly treat-
ment are often a significant proportion of household income [73]. Systems requiring
direct payment at the point of care prevent millions of people in the world from acces-
sing services and can result in financial hardship, and catastrophic health expenditure
which can drive individuals and families into poverty [74]. It is crucial therefore to en-
sure that wherever possible generic medications are used for the treatment of CVD.
This emphasizes the critical importance of efficient procurement channels for medi-
cines and diagnostic supplies in LMICs [69, 75], and ensuring that essential drugs are
free of charge [76]. Universal health coverage would be a major step forward in
ensuring that those with CVD and/or at risk of CVD have access to effective, affordable
and accessible health care [77, 78]. However, unframed improved access to health care
can create a number of distinct pressures that further prioritise curative clinical ser-
vices at the expense of population-level health promotion, prevention, and action on
social determinants of health, with a potential for less equitably distributed benefits
[68].
Conclusions
The high-risk strategy to reduce CVD risk in LMICs is an important component of any
program for CVD risk reduction in LMICs. High risk strategies need to be carefully
designed to maximize the numbers of fatal and non-fatal heart attacks and strokes
averted while minimizing the numbers of persons needing treatment. Concentrating
health care on those with high total CVD risk, as assessed by using CVD risk scores,
enables this to be done. Because of the enormous number of people at high CVD risk
in LMICs it is essential that care for high CVD risk among asymptomatic individuals is
centred on primary care, with secondary care being available for the acute management
of heart attack and stroke.
The increasing burden of NCDs in LMICs and the long-term management of CVD
and its risk factors mean that health systems in LMICs need to be rapidly orientated
around patient-centred integrated care for the management of NCDs [12, 79]. Valuable
lessons can be learnt from HIV/AIDS care in LMICs [80]. Among the many measures
to strengthen health systems, a number of specific issues are particularly relevant to the
management of persons at high CVD risk, including simplified treatment schemes, task
sharing, effective procurement of affordable medications, and universal access to health
care.
In addition to an effective health system response, the reduction of CVD and other
NCDs requires multisectoral population-based interventions to reduce their underlying
determinants.
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